Latest Breaking News On - Glaukos corporation - Page 15 : comparemela.com

Glaukos Co (NYSE:GKOS) Receives $87 30 Consensus Price Target from Brokerages

Glaukos Co. (NYSE:GKOS – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year target price among brokers that […]

Josephe gilliamAlexr thurmanPiper sandlerGlaukos corporationJpmorgan chase coGlaukos coSecurities exchange commissionTower research capitalNational bankSilverarc capital managementGet free reportExchange commissionCapital managementResearch capitalGet freeGlaukos daily

Insider Selling: Glaukos Co (NYSE:GKOS) COO Sells 9,476 Shares of Stock

Glaukos Co. (NYSE:GKOS – Get Free Report) COO Joseph E. Gilliam sold 9,476 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $94.12, for a total transaction of $891,881.12. Following the transaction, the chief operating officer now owns 119,802 shares of […]

Josephe gilliamYork mellon corpWells fargo companyMetlife investment managementGlaukos coGlaukos corporationMorgan stanleyNeedham companyHightower advisorsGet free reportTrading downNew york mellon corpTower advisorsMontreal canLife investment managementTruist financial

Allspring Global Investments Holdings LLC Raises Stock Holdings in Glaukos Co (NYSE:GKOS)

Allspring Global Investments Holdings LLC raised its position in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 17.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,827 shares of the medical instruments supplier’s stock after buying an additional 270 shares during […]

Piper sandlerJosephe gilliamThomas william burnsGlaukos corporationGlaukos coJpmorgan chase coAllspring global investments holdingsExchange commissionGeode capital managementVanguard group incGlaukos company profileSecurities exchange commissionMorgan stanleyFree reportGlobal investments holdingsStreet corp

Glaukos Corp s President & COO Joseph Gilliam Sells 9,476 Shares

Glaukos Corporation (NYSE:GKOS), a company specializing in the development and commercialization of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, has reported an insider sale according to a recent SEC filing.

Glaukos corpGlaukos corporationGlaukos corpJoseph gilliamInsider salesMarket price

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Chris lewisGlaukos corporationCorporate affairsConference callWebcast scheduledMicro invasive glaucoma surgeryInvestor relations